Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label
tabling member	label

Search

1135740

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they will place a copy of the World Health Organisation Global Advisory Committee on Vaccine Safety 2019 review of HPV vaccine safety in the Library of the House.
	tabling member printed	The Countess of Mar
	uin	HL16833
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>A meeting was held by the Global Advisory Committee on Vaccine Safety (GACVS) on 5 to 6 June 2019. However, the Medicines and Healthcare products Regulatory Agency is not aware of any formal review of human papillomavirus vaccine safety published by GACVS in 2019.</p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:24:58 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1861 label Biography information for The Countess of Mar

1135741

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mefloquine
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the European Medicines Agency Pharmacovigilance Risk Assessment Committee’s 2014 report on the toxicity of mefloquine (Larium).
	tabling member printed	The Countess of Mar
	uin	HL16834
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>At its meeting in February 2014, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended that the product information for mefloquine (Lariam) be amended to state that neuropsychiatric adverse reactions may persist for months, or longer, even after discontinuation of the drug. The Medicines and Healthcare products Regulatory Agency (MHRA) accepted the recommendations and implemented the advice of the PRAC, which is reflected in the United Kingdom product information for mefloquine. In addition, the MHRA has since taken further action to ensure that these risks are adequately conveyed to UK prescribers and patients in the form of improved checklists for healthcare professionals and a patient alert card.</p> answering member printed Baroness Blackwood of North Oxford question first answered 10/07/2019 15:26:45 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1861 label Biography information for The Countess of Mar

1135743

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mattresses: Fire Resistant Materials
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the risks to the neurological development of (1) foetuses, and (2) new-born children, of exposure to polyurethane mattresses treated with chlorinated phosphate flame retardants.
	tabling member printed	The Countess of Mar
	uin	HL16836
	answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment has considered the evidence on the potential effects of chlorinated and non-chlorinated phosphate flame retardants from all exposure sources, in general. The Committee is preparing a statement on phosphate-based flame retardants and the potential for neurodevelopmental toxicity. It is expected that the statement will be published in summer 2019.</p><p>Chlorinated organophosphorous flame retardants are regulated under the European Union REACH (Restriction, Evaluation, Authorisation and Restriction of Chemicals) regime. The United Kingdom has been proactive in supporting the regulation of flame retardants through REACH. The European Chemicals Agency has announced an intention to restrict a number of chlorinated flame retardants. It is expected that the restriction proposal will be submitted in July 2019, followed by a public consultation.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 15/07/2019 10:24:38 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1861 label Biography information for The Countess of Mar

1135744

	registered interest
	date	01/07/2019
	answering body	Ministry of Defence
	answering dept id	11
	answering dept short name	Defence
	answering dept sort name	Defence
	hansard heading	Malaria: Drugs
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether the health and wellbeing of all participants in the Surgeon-General’s 2016–17 research study on anti-malarial chemoprophylaxis (Ref: 713/MoDREC/15) was monitored to ensure that all adverse events occurring during the study were reported to the Medicines and Healthcare products Regulatory Agency (MHRA); whether participants have been monitored following the study to ensure that any adverse events that have occurred since are being reported to the MHRA; and what assessment they have made of whether suitable treatment is available to those participants suffering adverse events.
	tabling member printed	The Countess of Mar
	uin	HL16837
	answer	answer is ministerial correction date of answer 08/07/2019 answer text <p>Adverse events are reported to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow card scheme and can be undertaken by a healthcare professional or the individual experiencing the adverse effect. The demographics required by the Yellow card scheme do not include the occupation of the subject, so military personnel are not uniquely identified.</p><p>The aims of the &quot;713/MoDREC/15&quot; study do not include assessing whether individuals or their healthcare professional reported side effects to the MHRA or to follow-up whether any person experiencing side effects required any form of treatment, including an assessment of whether suitable treatment was available. Data collated in the study is self-reported by individuals and any symptoms reported may not necessarily be related to the anti-malarial taken.</p> answering member printed Earl Howe question first answered 08/07/2019 16:39:39 answering member 2000 label Biography information for Earl Howe
	tabling member	1861 label Biography information for The Countess of Mar

1135742

	registered interest
	date	01/07/2019
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Furniture: Fire Resistant Materials
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they have assessed the environmental risks of disposing of polyurethane used in furniture which has been treated with tris (1-chloro-2-propyl) phosphate (TCIPP).
	tabling member printed	The Countess of Mar
	uin	HL16835
	answer	answer is ministerial correction date of answer 10/07/2019 answer text <p>Tris (1-chloro-2-propyl) phosphate (TCIPP) is also known by its regulatory process name, tris (2-chloro-1-methylethyl) phosphate (TCCP).</p><p> </p><p>The Environment Agency worked with chemical authorities in the Republic of Ireland to initially assess the risks of TCPP in 2008. The potential environmental and human health risks of TCPP in products and other objects are currently being considered by the European Chemicals Agency (ECHA) and European Union member state scientists. Subsequently, building on a greater body of evidence, the ECHA, supported by Danish and German work are evaluating the properties of this substance and considering a legal restriction on it.</p><p> </p><p>Further information on this is expected soon and will help identify the chemical properties and environmental risks from TCPP in products like furniture.</p> answering member printed Lord Gardiner of Kimble question first answered 10/07/2019 15:30:43 answering member 4161 label Biography information for Lord Gardiner of Kimble
	tabling member	1861 label Biography information for The Countess of Mar